2025 Annual Financial Settlement Report
Yantai Zhenghai Biotechnology Co., Ltd.
The operating and financial results for the year 2025 have been audited and confirmed by Tianzhi International Accounting Firm (Special General Partnership), with the results as follows:
(1) Balance Sheet
Unit: Ten Thousand Yuan
| Item/Year | End of 2025 | End of 2024 | Change Rate |
|---|---|---|---|
| Cash and Cash Equivalents | 6,199 | 11,684 | -47% |
| Trading Financial Assets | 57,511 | 50,543 | 14% |
| Notes Receivable | 0 | 33 | -100% |
| Accounts Receivable | 5,718 | 4,850 | 18% |
| Financing Receivables | 142 | 194 | -27% |
| Prepayments | 674 | 344 | 96% |
| Other Receivables | 141 | 64 | 120% |
| Inventory | 2,955 | 3,518 | -16% |
| Other Current Assets | 0 | 40 | -100% |
| Total Current Assets | 73,339 | 71,270 | 3% |
| Fixed Assets | 21,366 | 22,874 | -7% |
| Investment Properties | 0 | 7 | -100% |
| Construction in Progress | 115 | 134 | -14% |
| Intangible Assets | 2,996 | 3,253 | -8% |
| Long-term Deferred Expenses | 0 | 2 | -100% |
| Deferred Tax Assets | 117 | 233 | -50% |
| Other Non-current Assets | 529 | 238 | 122% |
| Total Non-current Assets | 25,123 | 26,741 | -6% |
| Total Assets | 98,462 | 98,011 | 0% |